VA's McKesson Pharmaceutical Prime Vendor contract nears $839M in FY24, highlighting critical drug supply chain management

Contract Overview

Contract Amount: $838,785,945 ($838.8M)

Contractor: Mckesson Corporation

Awarding Agency: Department of Veterans Affairs

Start Date: 2024-06-01

End Date: 2024-06-30

Contract Duration: 29 days

Daily Burn Rate: $28.9M/day

Competition Type: FULL AND OPEN COMPETITION

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2024 JUNE

Place of Performance

Location: IRVING, DALLAS County, TEXAS, 75039

State: Texas Government Spending

Plain-Language Summary

Department of Veterans Affairs obligated $838.8 million to MCKESSON CORPORATION for work described as: EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2024 JUNE Key points: 1. The contract ensures a steady supply of pharmaceuticals to VA facilities, a crucial component of veteran healthcare. 2. As a prime vendor, McKesson manages a broad catalog, potentially offering economies of scale and streamlined procurement. 3. The contract's duration and value suggest a significant reliance on this vendor for essential medical supplies. 4. Performance context is vital; ongoing monitoring of delivery timeliness and product quality is essential for patient care. 5. The sector positioning is within the broader healthcare and pharmaceutical distribution market, a highly regulated and competitive space.

Value Assessment

Rating: good

The VA's Pharmaceutical Prime Vendor (PPV) program, with McKesson as a key contractor, represents a significant investment in ensuring access to necessary medications. While specific per-unit cost comparisons are not readily available without detailed product-level data, the overall contract value of approximately $839 million for FY24 suggests a substantial volume of pharmaceutical goods and services. Benchmarking against similar large-scale prime vendor contracts within federal healthcare would provide a clearer picture of value for money, but the program's longevity indicates a recognized benefit in consolidating pharmaceutical procurement.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

This contract was awarded under full and open competition, indicating that multiple qualified vendors had the opportunity to bid. The specific number of bidders is not provided in the summary data, but the 'full and open' designation suggests a competitive process designed to solicit the best value. This approach typically leads to more favorable pricing and service terms for the government compared to sole-source or limited competition awards.

Taxpayer Impact: A full and open competition process for such a large and critical contract is beneficial for taxpayers as it encourages competitive pricing and potentially drives innovation in pharmaceutical distribution services, ultimately aiming for cost savings and improved service delivery.

Public Impact

Veterans across the nation benefit from consistent access to a wide range of pharmaceuticals through VA healthcare facilities. The contract supports the delivery of essential prescription medications, contributing directly to the health and well-being of beneficiaries. Geographic impact is nationwide, as the VA serves veterans in all states and territories. Workforce implications include roles within McKesson for logistics, distribution, and customer service, as well as VA personnel managing the program.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Potential for price increases over contract duration if not adequately managed.
Dependence on a single prime vendor could create supply chain vulnerabilities.
Ensuring equitable distribution across all VA facilities requires robust logistical oversight.

Positive Signals

Demonstrated ability to manage large-scale pharmaceutical distribution.
Full and open competition suggests a competitive pricing structure.
Long-standing relationship indicates a level of trust and operational efficiency.

Sector Analysis

The pharmaceutical distribution sector is a critical component of the healthcare industry, characterized by complex supply chains, stringent regulatory requirements, and significant market concentration. Prime vendor contracts like this one are essential for large healthcare providers, such as the Department of Veterans Affairs, to manage the procurement and delivery of a vast array of medications efficiently. The total federal spending on pharmaceutical prime vendor services is substantial, reflecting the ongoing need for reliable drug supply across various government agencies.

Small Business Impact

The provided data does not indicate any specific small business set-asides or subcontracting requirements for this particular contract. As a prime vendor contract, the primary focus is on the large-scale distribution capabilities of the prime contractor. While McKesson may engage small businesses in its broader operations, this contract's structure does not appear to directly prioritize small business participation as a set-aside. Further analysis of subcontracting plans would be needed to assess the impact on the small business ecosystem.

Oversight & Accountability

Oversight for this contract is primarily managed by the Department of Veterans Affairs, likely through its procurement and logistics departments. Accountability measures would include performance metrics, delivery schedules, and quality control standards outlined in the contract. Transparency is generally facilitated through contract award databases and reporting requirements. The VA's Office of Inspector General may also conduct audits or investigations into the program's effectiveness and compliance.

Related Government Programs

Federal Supply Schedule (FSS) contracts for pharmaceuticals
Department of Defense TRICARE Pharmacy Program
General Services Administration (GSA) Schedules
Other agency pharmaceutical procurement contracts

Risk Flags

Supply Chain Risk
Vendor Lock-in Potential
Price Volatility
Performance Monitoring Needs

Frequently Asked Questions

What is this federal contract paying for?

Department of Veterans Affairs awarded $838.8 million to MCKESSON CORPORATION. EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2024 JUNE

Who is the contractor on this award?

The obligated recipient is MCKESSON CORPORATION.

Which agency awarded this contract?

Awarding agency: Department of Veterans Affairs (Department of Veterans Affairs).

What is the total obligated amount?

The obligated amount is $838.8 million.

What is the period of performance?

Start: 2024-06-01. End: 2024-06-30.

What is McKesson Corporation's track record with federal pharmaceutical contracts, particularly with the VA?

McKesson Corporation is a major player in the pharmaceutical distribution industry and has a long history of serving federal agencies, including the Department of Veterans Affairs. They have held significant prime vendor contracts with the VA for many years, managing the complex logistics of supplying a wide range of pharmaceuticals to VA medical centers and clinics nationwide. Their extensive experience in this area suggests a deep understanding of federal procurement regulations, supply chain management, and the specific needs of government healthcare systems. While specific performance metrics for past contracts are not detailed here, their continued success in securing and performing on large federal contracts indicates a generally positive track record and established capabilities in fulfilling these critical roles.

How does the value of this contract compare to previous years or similar contracts with other federal agencies?

The FY24 value of approximately $838.8 million for the VA's Pharmaceutical Prime Vendor (PPV) contract with McKesson represents a substantial commitment. Without historical data for this specific contract or direct comparisons to other agencies' prime vendor contracts, a precise benchmark is difficult. However, the pharmaceutical distribution market is characterized by large-volume contracts due to the nature of the goods. The VA's extensive network of healthcare facilities necessitates significant pharmaceutical spending. Comparing this to contracts held by other large federal healthcare providers like the Defense Health Agency (DHA) or the Bureau of Prisons would offer more context. Generally, such prime vendor contracts are valued in the hundreds of millions to billions of dollars annually, depending on the size and scope of the agency served.

What are the primary risks associated with relying on a single prime vendor for pharmaceutical supply?

Relying on a single prime vendor like McKesson for pharmaceutical supply introduces several key risks. Firstly, there's a risk of supply chain disruption; unforeseen events such as natural disasters, labor strikes, or global health crises could impact McKesson's ability to deliver, potentially leading to drug shortages within the VA system. Secondly, a lack of robust competition could lead to less favorable pricing over time, as the vendor may have reduced incentive to offer the most competitive rates if alternatives are limited. Thirdly, there's a risk of vendor performance issues, such as delivery delays or quality control problems, which could directly impact patient care. Finally, over-reliance can create a dependency that makes it difficult to switch vendors or adapt quickly to changing market conditions or technological advancements in pharmaceutical distribution.

How effective is the Pharmaceutical Prime Vendor (PPV) program in ensuring timely and cost-effective access to medications for veterans?

The Pharmaceutical Prime Vendor (PPV) program, as managed by the VA with contractors like McKesson, is generally considered an effective mechanism for ensuring timely and cost-effective access to medications for veterans. By consolidating procurement through a prime vendor, the VA can leverage bulk purchasing power, streamline ordering processes, and benefit from the vendor's established distribution network, which often ensures rapid delivery to facilities nationwide. This approach reduces the administrative burden and logistical complexity compared to managing numerous individual contracts with different drug manufacturers. While 'cost-effective' is relative and depends on competitive bidding and ongoing oversight, the program's structure is designed to achieve economies of scale. The timeliness of access is critical for patient care, and prime vendors are typically held to strict delivery performance standards.

What is the typical duration and renewal cycle for such large federal pharmaceutical prime vendor contracts?

Large federal pharmaceutical prime vendor contracts, like the VA's PPV program, typically have an initial base period of performance, often one year, followed by multiple one-year option periods. The total potential duration, including all option periods, can extend for several years, often up to five years or more, depending on the contract's structure and the agency's needs. For example, a contract might have a 1-year base period and four 1-year option periods, totaling a 5-year potential duration. Renewal is not automatic; it depends on the government exercising its option to extend the contract, which is usually contingent upon satisfactory performance, continued need for the services, and availability of funds. The process often involves re-competition before the end of the potential term to ensure continued best value.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing

Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Address: 6555 STATE HIGHWAY 161, IRVING, TX, 75039

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $838,785,945

Exercised Options: $838,785,945

Current Obligation: $838,785,945

Contract Characteristics

Multi-Year Contract: Yes

Commercial Item: COMMERCIAL PRODUCTS/SERVICES

Cost or Pricing Data: NO

Parent Contract

Parent Award PIID: 36W79720D0001

IDV Type: IDC

Timeline